XPENG-MOTORS
14.3.2022 14:34:04 CET | Business Wire | Press release
XPENG, a leading smart electric vehicle and mobility technology company, today announced that it has joined three major European automobile associations, the European Association for Electromobility (AVERE), Royal RAI Vereniging / RAI Association (RAI) and BIL Sweden, underlining the company's long-term commitment to developing the smart and greener mobility ecosystem in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220314005486/en/
Leveraging its strong expertise in innovative technology and sustainable mobility, XPENG will bring valuable insights in the smart EV sector, contributing to the development and implementation of the European Commission's Sustainable and Smart Mobility Strategy.
“We appreciate the extraordinary commitment that Europe has made to carbon neutrality and sustainable mobility,” said Leon He, Vice President of XPENG. “Our vision is to transform future mobility with technology. By consolidating our industry connections and actively engaging with the European automobile sector, we hope to accelerate the development of electrification, digitization and automation technologies for the auto sector. XPENG will continue to invest in innovations and is excited to work together with automobile stakeholders in Europe to achieve our shared vision: building a sustainable mobility ecosystem for the future.”
AVERE is the leading European association that promotes electromobility and sustainable transport across Europe. It represents and advocates for electromobility on behalf of the industry, academia, and EV users at both EU and national levels.
“We at AVERE are delighted to welcome XPENG as a member as it continues to develop and invest in Europe,” said Philippe Vangeel, Secretary-General of AVERE. “We look forward to engaging and working together with XPENG in shaping the future of smart and sustainable mobility.”
The Royal RAI Vereniging represents the interests of enterprises in the mobility sector in the Netherlands, and plays an active role in facilitating the production and sales of vehicles and parts for its 700 members, who together supply all forms of road transportation.
Steven van Eijck, Chairman of the Royal RAI Vereniging, commented: “We are very happy to welcome XPENG as our new member. XPENG plays an important role in the rapidly growing market for electric mobility, particularly passenger cars in the world. This is essential as we transition towards a zero-emission mobility system to meet our environmental and climate goals. The Dutch passenger car market is leading the initiatives in Europe when it comes to electrification. It acts as a gateway to the European passenger car market and is therefore attractive for newcomers.”
BIL Sweden is the Swedish industry organization for manufacturers and importers of cars, trucks and buses. The member companies together account for around 97 percent of new car sales in Sweden. The organization acknowledges that vehicles are a key player in the sustainable society focused on climate and environmental issues, safety and mobility development. BIL Sweden's vision for the year 2030: building long-term sustainable mobility and transportation solutions.
"BIL Sweden aims to work for a society that achieves its climate goals through developing long-term carbon-neutral strategies that promote energy efficiency and renewable energy vehicles. We believe that fossil fuels can be gradually phased out and replaced with renewable fuels and electrification as we improve energy efficiency. We are confident that companies like XPENG, which are focused on electric power, technology and innovation, are well positioned to contribute to this development. I am really looking forward to having them in BIL Sweden," said Mattias Bergman, CEO of BIL Sweden.
Earlier, XPENG announced the opening of its first European Experience Stores in Sweden and the Netherlands, and its partnership with Bilia and Emil Frey Nederland NV to build a first-class distribution, sales and service network in Sweden and the Netherlands, respectively.
The company is committed to Europe’s carbon-neutral initiatives and is dedicated to building intelligent, sustainable and people-first mobility solutions. XPENG differentiates itself with its full-stack in-house Advanced Driver Assistance System (ADAS) technologies and in-car intelligent operating system, as well as core vehicle systems including powertrain and electrification/electronic architecture, providing superior and safe mobility experience a growing base of customers.
About XPENG
https://heyxpeng.com/
About AVERE
https://www.avere.org/what-is-avere/
About Royal RAI Vereniging / RAI Association
https://www.raivereniging.nl/automotiveindustrynl/over-ons
About BIL Sweden
https://www.bilsweden.se/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005486/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom